Wegovy’s supply + brewing competition concerns overshadow a decent Q2
04/08/22 -"In Q2, Novo continued its strong run, driven by strong growth momentum seen in both Obesity and GLP-1 Diabetes franchise. However, emerging and potential competition from Eli Lilly’s Mounjaro in ..."
Pages
73
Language
English
Published on
04/08/22
You may also be interested by these reports :
23/10/25
The Q3 sales missed expectations by a small margin; however, the management upgraded its 2025 earnings outlook. The Pharmaceuticals segment was again ...
23/10/25
Lonza’s strong Q3 commentary reaffirmed its commitment to meeting the 2025 guidance, boosting investor sentiment. While operational figures were not ...
22/10/25
Ipsen’s Q3 sales surpassed expectations, showing robust growth across all segments. Consequently, the 2025 guidance has been revised upwards. The ...
20/10/25
“Only when the tide goes out do you discover who’s been swimming naked.” This famous line from Warren Buffett fits well for the ...